Protara Therapeutics
TARA
28 hedge funds and large institutions have $12.6M invested in Protara Therapeutics in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 11 reducing their positions, and 4 closing their positions.
1% more capital invested
Capital invested by funds: $12.5M → $12.6M (+$109K)
0.09% more ownership
Funds ownership: 1.09% → 1.18% (+0.09%)
0% more funds holding
Funds holding: 28 → 28 (0)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
73% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$1.87M |
| 2 |
Renaissance Technologies
New York
|
+$100K |
| 3 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$22.9K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$15K |
| 5 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
+$7.84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$151K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$126K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$53.8K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$52K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$36.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1K | -$56 | -1 | -8% |
|
|
27
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$126K | -1,807 | Closed |
|
|
28
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$52K | -739 | Closed |
|
29
Citadel Advisors
Miami,
Florida
| – | -$22K | -312 | Closed |
|
|
AIM
30
Acrospire Investment Management
Chicago,
Illinois
| – | -$1K | -12 | Closed |
|
31
Morgan Stanley
New York
| – | +$448 | +8 | New |
|
TARA Hedge Fund Activity: Q2 2017 in Review
28 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q2 2017, worth a combined $12.6M — up 0.87% from $12.5M a quarter earlier.
Fund positioning in TARA was balanced in Q2 2017: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 11 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $1.87M. The largest seller was Deerfield Management, cutting an estimated $151K.
- 28 institutional investors held Protara Therapeutics (TARA) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $12.6M of Protara Therapeutics stock for Q2 2017, up 0.87% quarter-over-quarter.
- 4 funds opened new Protara Therapeutics positions in Q2 2017 and 4 closed out, a net change of 0 holders.
- The largest Protara Therapeutics buyer in Q2 2017 was RA Capital Management, an estimated $1.87M added.
- The largest Protara Therapeutics seller in Q2 2017 was Deerfield Management, an estimated $151K sold.
Based on aggregated 13F filings for Q2 2017.